Business
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be
About this update from Exagen Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) virtual annual meeting, ACR Convergence 2021. The event is being held online from November 6-9, 2021. Exagen’s Chief Scientific Officer, Anja Kammesheidt, shared, “Exagen is honored to have had the opportunity to partner with such great collaborators on this year’s abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus, and to contribute to advancing patient care. We are pleased to be sharing this data at this year’s virtual ACR event.” Below is the list of accepted abstracts along with links to each: Saturday, November 6th Poster Presentation | Presented by Roberta Alexander, PharmD, PhD | Abstract #0325Title: A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356)Session Time: 8:30am – 10:30am ET Poster Presentation | Presented by Richard Ramonell, MD | Abstract #0003Title: Clinically Identifiable Autoreactivity is Common in Severe SARS-CoV-2 Infection Session Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease PosterSession Time: 8:30am – 10:30am ET Poster Presentation | Presented by Matthew Woodruff, PhD | Abstract #0010Title: Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19Session Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster Session Time: 8:30am – 10:30am ET Poster Presentation | Presented by Tyler O’Malley, BS | Abstract #0336Title: The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products Versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356) Session Time: 8:30am – 10:30am ET Sunday, November 7th Poster Presentation | Presented by Jennifer Rogers, MD | Abstract #0868Title: Cell-bound Complement Activation Products (CB-CAPs) Pre...